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Background: Omalizumab is a monoclonal antibody indicated for treatment of severe
persistent allergic asthma inadequately controlled despite optimal controller therapy. We
investigated whether patient selection could be targeted further.
Methods: Data from seven randomized controlled omalizumab trials were analyzed to
investigate whether pre-treatment patient baseline clinical characteristics could be
identified that were predictive of a superior response to omalizumab. We also studied
whether patients who respond to omalizumab following a course of treatment could be
reliably identified. Univariate/multivariate analyses of INNOVATE data were performed to
identify predictive baseline measures and further investigated in efficacy analyses of
pooled data from seven studies. The best method of identifying responders to omalizumab
following treatment was determined by assessing the ability of various clinical response
criteria to identify responders and discriminate patient exacerbation and other outcomes.
Results: Baseline total immunoglobulin E (IgE) was the only predictor of efficacy in
INNOVATE. However, pooled analysis showed treatment benefits irrespective of IgE levels.
In omalizumab-treated patients, physician’s overall assessment following a course of
treatment identified 61% as responders and best discriminated treatment outcomes.Elsevier Ltd. All rights reserved.
33 61 04; fax: +33 467 04 27 08.
nadoo.fr (J. Bousquet).
ARTICLE IN PRESS
J. Bousquet et al.1484Conclusion: Baseline characteristics do not reliably predict benefit with omalizumab.
Physician’s overall assessment after 16 weeks of treatment is the most meaningful measure
of response to therapy.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Omalizumab is a monoclonal anti-immunoglobulin E (IgE)
antibody indicated for the treatment of asthma in patients
with inadequately controlled severe persistent allergic
asthma despite optimal controller therapy. As the first
monoclonal antibody indicated for the treatment of asthma,
omalizumab represents a new paradigm for asthma therapy
and a new challenge for prescribers. Although omalizumab
has proven efficacy in moderate-to-severe and severe
persistent allergic asthma1–10 and is indicated for the
treatment of a highly targeted population, it is important
to further refine the patient population to identify patients
who will gain most benefit from omalizumab therapy and
optimize use of healthcare resources.
In a pooled analysis of two earlier randomized placebo-
controlled trials,4,6 factors indicative of more severe asthma
(history of emergency treatment, low forced expiratory
volume in 1 s (FEV1) and high-dose inhaled corticosteroids
(ICS)) were predictive of a greater relative response to add-
on omalizumab.11 These data need to be extended to a
wider patient population and patients with the most severe
asthma. In addition, it is important to be able to evaluate
treatment response to omalizumab after a period of
treatment. In a recent study, basophil allergen sensitivity
was proposed as a useful approach for evaluating efficacy to
omalizumab therapy.12 However, the study was not designed
to demonstrate a correlation between reduced basophil
sensitivity and improved asthma control.
Reductions in exacerbations and emergency interventions
(hospitalizations or emergency room visits) are the most
important outcome of therapy in patients with severe
asthma. These discrete events occur relatively infrequently
and are, therefore, of little pragmatic clinical use for
assessing response in individual patients. There is growing
evidence that broad markers of asthma control that measure
a range of outcomes provide more meaningful information
than traditional single specific markers.13–15 The concept of
overall asthma control15,16 may be especially relevant in
severe asthma as it takes into account many aspects of
clinical disease. However, complete control is more difficult
to achieve as disease severity increases.15 In assessing
response to treatment, failure to meet threshold-based
criteria does not necessarily reflect a smaller treatment
benefit, but may reflect a more severe less well-controlled
patient population prior to treatment. The Global Initiative
for Asthma (GINA) guidelines acknowledge this by recogniz-
ing that asthma control may not be possible in many patients
with severe persistent asthma.17
The aim of this analysis was to investigate whether
patient selection for omalizumab therapy in an already
highly targeted population could be further enhanced. Data
from seven randomized controlled omalizumab trials were
analyzed to investigate whether pre-treatment patientbaseline clinical characteristics could be identified that
were predictive of a superior response to omalizumab. We
also studied whether patients who respond to omalizumab
following a course of treatment could be reliably identified.Methods
Five trials included in these post hoc analyses were
randomized, double-blind, placebo-controlled studies1,3,4–8
and two were randomized, controlled open-label studies.2,9
In all studies, omalizumab was given as add-on therapy to
concomitant asthma treatment and administered subcuta-
neously every 2 or 4 weeks according to patients’ pre-
treatment bodyweight and baseline IgE levels using a dosing
table. The designs of these studies are described in detail
elsewhere.1–9 All trials were of X24 weeks’ duration, and
enrolled patients with allergic asthma. Patients enrolled in
the INNOVATE study1 had inadequately controlled severe
persistent allergic asthma despite GINA 2002 step 4 therapy
(high-dose ICSs plus a long-acting b2-agonist (LABA) 7addi-
tional controller medication). Approximately 60% of patients
were receiving additional controller medication (including
maintenance oral corticosteroids (22%), leukotriene modi-
fiers (35%) and theophyllines (27%)), which was optimized
prior to the 28-week treatment phase. Overall, 93% of the
pooled patient population (X12 years of age) across the
seven studies met GINA criteria for severe persistent
asthma.10 Further details of the pooled population have
been published previously.10Part I: ability of pre-treatment baseline measures to
predict response to omalizumab
Initial exploratory univariate and multivariate analyses of
data from the INNOVATE study1 were conducted, with no
pre-specified hypotheses to be tested. The baseline char-
acteristic identified as consistently important in the
univariate and multivariate analyses was further investi-
gated in exploratory efficacy subgroup analysis of pooled
data from all seven trials.2–9Univariate and multivariate analyses
The univariate analysis considered 232 regression analyses
based on eight response measures and 29 baseline variables
(Table 1(a)) in the INNOVATE study. Poisson or logistic
regression models were used for each response measure, as
appropriate, and the interaction with baseline variables
determined. Baseline variables that demonstrated a sig-
nificant interaction with treatment were included in the
multivariate analyses, which evaluated the predictive value
of combinations of baseline variables for each response
variable, using Poisson or logistic regression, as appropriate.
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Table 1 Assessment of pre-treatment baseline measures (a and b) and methods for evaluating response (c).
(a) Univariate analysis
Response measures
Number, incidence and rate of clinically significant asthma exacerbations (worsening of asthma requiring systemic
corticosteroids); number and incidence of severe exacerbations (PEF or FEV1o60% of personal best and requiring treatment
with systemic corticosteroids); asthma-related quality of life (% patients with X0.5 point increase in total AQLQ score18,19;
physician’s overall assessment (% patients judged to have complete control of asthma or marked improvement)4; lung
function (% patients with X200mL improvement in FEV1)
20
Baseline variables
Overall AQLQ score; ICS; oral corticosteroids used; GINA clinical features; mould allergy; exacerbations in the previous year;
sex; age; weight; height; smoker; IgE; per cent predicted FEV1; duration of asthma; number of positive allergens; qualifying
FEV1 reversibility; in hospital last year; ever intubated; emergency room last year; doctor last year; missed school/work last
year; nocturnal symptom score; daytime symptom score; total symptom score; morning symptom score; morning PEF; rescue
medication use; schedule; time since previous exacerbation
(b) Pooled efficacy subgroup analysis
Asthma exacerbation ratey, severe exacerbation rate (PEF or FEV1o60% oro50% (study dependent) of personal best and
requiring treatment with systemic corticosteroids), total emergency visit rate (hospital admissions, emergency room visits and
unscheduled doctor’s visits), FEV1 clinically meaningful net benefit (% patients with improvement in FEV1X200mL minus %
patients with aX200mL worsening),20X0.5-point increase in overall AQLQ score,18,19 and the physician’s overall assessment
(complete control of asthma or marked improvement)6
(c) Responder definitions assessed for evaluating response to omalizumab
Physician’s overall assessment (complete control of asthma or marked improvement),4; X0.5 point improvement in total
AQLQ score18,19; X200mL improvement in FEV1
20; X1.0 point reduction in daytime symptom score (4-point scale: 0 ¼ no
symptoms, 4 ¼ major discomfort)6; X1.0 point reduction in nocturnal symptom score (4-point scale: 0 ¼ no symptoms,
4 ¼ major discomfort)6; and reduction X1/week and by at least 50% in night awakenings
Five-level evaluation: complete control, marked improvement in control, discernible but limited control, no appreciable change,
worsening in control.
yDefined as worsening of asthma requiring systemic corticosteroids in three studies1,2,8 and as a worsening requiring systemic
corticosteroids or doubling of ICS doses in three studies4–7 (90% of events required systemic corticosteroids). One study9 defined
exacerbations as a worsening of asthma requiring systemic corticosteroids or a doubling of ICS plus an emergency room visit or
hospitalization (94% of exacerbations were treated with systemic corticosteroids).
Predicting response to omalizumab in asthma 1485Pooled subgroup analysis
Baseline total IgE was the only baseline characteristic
identified as consistently important in the univariate and
multivariate analyses (see results). Pooled data from all
seven studies were used to obtain sufficient patient numbers
over a wide range of IgE levels; this subgroup analysis was
conducted within four quartiles based on baseline total IgE
(IU/mL: 0–75, 76–147, 148–273,X274). The use of pooled
data was considered valid as all patients had allergic asthma
(93% severe persistent), had a similar range of baseline IgE
levels and used the same 2- or 4-weekly dosing regimen.
Outcome variables assessed according to baseline total IgE
are shown in Table 1(b).Part II: identifying patients who respond to
omalizumab therapy
To identify patients who respond to omalizumab therapy, a
preliminary analysis was conducted on efficacy results from
the INNOVATE study1 and extended to include the four
additional randomized, double-blind, placebo-controlled
trials.2,4–8 The two open-label studies3,9 were not included
in this analysis as not all response measures evaluated were
included in those studies. The analysis consisted of four
main steps: (1) identification of an effective and accuratemeasure of response to omalizumab, with a clinically
relevant threshold, that could select responders who
achieved control in terms of exacerbations (see
Table 1(c)); (2) assessment of whether these responders
also showed improvements across a range of other measures
of asthma control (healthcare utilization, symptoms, rescue
medication use, FEV1 and asthma-related quality of life) by
evaluating outcomes in responders and non-responders
according to the selected response measure; (3) a utility
analysis to identify objective clinical measures (including
combinations of measures) that could identify responders to
the selected response measure; sensitivity (proportion of
true positive response that has a positive test result) and
specificity (proportion of true negative response that has a
negative test result) for detecting the selected response
measure were determined (4) a comparison of exacerbation
rates in omalizumab-treated patients who were responders
according to the selected response definition and an
omalizumab-treated patient population with total baseline
IgEX76 IU/mL. Rate ratios (omalizumab:placebo) for ex-
acerbations rates were calculated in the INNOVATE study for
the overall omalizumab-treated population, responders to
omalizumab (by the selected response measure), omalizu-
mab-treated patients with total baseline IgEX76 IU/mL,
and omalizumab responders who also had total baseline
IgEX76 IU/mL.
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J. Bousquet et al.1486In the first step, the initial assessment of the ability of
response criteria to discriminate exacerbation outcomes
was investigated for six responder definitions described in
Table 1(c). These included a physician’s overall assessment
of asthma control, a composite measure that encompasses
multiple aspects of response. It is based upon clinical
assessments including patient interviews, review of medical
notes, spirometry and diaries of symptoms, rescue medica-
tion use and peak expiratory flow. In omalizumab clinical
trials, a physician’s overall assessment was graded in a five-
level evaluation of asthma control: complete control;
marked improvement in control; discernible but limited
control; no appreciable change; worsening in control.
Responders are defined as those with marked improvement
or complete control.
Results
Part I: predictive value of pre-treatment baseline
characteristics
Univariate and multivariate analyses (INNOVATE study)
Baseline IgE concentration had an interaction with asthma
exacerbations (number of exacerbations, P ¼ 0.004; inci-
dence of exacerbations, P ¼ 0.070; reduction in exacerbation
rate, P ¼ 0.032), quality of life (P ¼ 0.031) and the physi-
cian’s overall assessment (P ¼ 0.026) (Table 2). Lower base-
line IgE was associated with a smaller treatment benefit.
Height and lung function had interactions with some response
variables, but unlike IgE, were not consistent (Table 2).
Similarly, in the multivariate analysis, baseline IgE was the
only variable with predictive value, whereas inconsistent
results were obtained for height and lung function.
Subgroup analysis according to baseline IgE (pooled data)
In the omalizumab-treated patients, asthma exacerbation
rate was reduced across all IgE levels, reaching statistically
significant decreases in each of the three upper IgE quartiles
(40–50% decrease vs. control; Table 3). In contrast, severe
exacerbation rates decreased by 40–70% in omalizumab-
treated patients, compared with control recipients, across
all four quartiles, with statistically significant differences in
quartiles 1, 3 and 4 (Table 3).
Total emergency visit rates were significantly reduced by
30–60% compared with control for the three upper quartiles.
Proportions of responder for clinically meaningful Asthma
Quality of Life Questionnaire (AQLQ) improvement and FEV1
net benefit favoured omalizumab-treated patients in the
three upper IgE quartiles (Table 3). Significant improve-
ments in physician’s overall assessment (complete control/
marked improvement in symptoms) were seen in all IgE
quartiles.
Part II: identifying patients who respond to
omalizumab
Selection of the most appropriate measure of response
for omalizumab
In this first step, we sought to identify an effective and
accurate measure of response to omalizumab that coulddiscriminate exacerbation outcomes in responders com-
pared with non-responders.
INNOVATE study
All response measures evaluated (with the exception of FEV1
improvements) were able to discriminate exacerbation
outcome. Responders identified by physician’s overall
assessment (complete control or marked improvement)
and AQLQ (X0.5-point improvement) had markedly fewer
clinically significant exacerbations (worsening of asthma
requiring systemic corticosteroids) than non-responders
(Table 4). Responders classified according to daytime
symptoms, nocturnal symptoms and night awakenings were
also able to discriminate exacerbation outcomes (Table 4).
Physician overall evaluation and AQLQ were able to identify
a greater proportion of responders (61% of omalizumab-
treated patients as responders) compared with single-item
measures (18–32% of patients), while maintaining a similar
discrimination for exacerbation outcomes.
A large proportion of omalizumab patients identified as
responders by the broader measures of response were also
classed as responders by the other single-item response
measures, whereas responders according to FEV1, daytime
symptoms, nocturnal symptoms and night awakenings were
not (Table 5). Using single-item measures to assess response
to omalizumab is not appropriate as these would lead to at
least 50% of true responders being classified as non-
responders (false negative). The broader measures of
response classification were examined further to select the
best measure of evaluating response to omalizumab.
Physician’s overall assessment was also able to discrimi-
nate for severe asthma exacerbations (FEV1 or peak
expiratory flow (PEF) o60% of personal best and requiring
systemic corticosteroids). However, severe exacerbation
rate was similar in both responders and non-responders
according to AQLQ. Annualized rate (SD) for physician’s
overall assessment responders was 0.2 (0.6) compared with
1.4 (6.1) for non-responders. The corresponding rates for
AQLQ were 0.4 (1.1) for responders and 0.4 (1.2) for non-
responders. Based on these data, the physician’s overall
assessment was selected as the best definition of response.
Pooled analysis
The proportion of patients identified as omalizumab
responders by physician overall assessment was similar to
that seen in INNOVATE (61% (665/1,085)). In the pooled
analyses, the improvements in exacerbation rates among
omalizumab-treated patients identified as responders were
greater than in non-responders with similar findings to the
analysis of INNOVATE data (rate (SD); responders: 0.4 (0.9);
non-responders: 1.1 (3.1)).
Ability of the physician’s overall assessment to
discriminate other measures of asthma control
Patients identified as responders according to the physi-
cian’s overall assessment had greater benefits for all clinical
outcomes in both INNOVATE (Table 6) and the pooled
populations (data not shown), with marked improvements
in asthma control and healthcare utilization. Using the
threshold of at least marked improvement in asthma control
in the physician’s overall assessment, there was 83.5%
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Table 2 Treatment by baseline variable interactions: univariate analysis.
Baseline variable P-value Direction of most benefit
from omalizumab
Number of clinically significant exacerbations
IgE 0.004 High
Height 0.018 Low
Per cent predicted FEV1 0.027 Low
Number of exacerbations in previous year 0.031 High
Schedule 0.039 2 weekly
Weight 0.048 Low
Incidence of any clinically significant exacerbations
Per cent predicted FEV1 0.047 Low
IgE 0.070 High
Height 0.088 Low
Reduced clinically significant exacerbation rate (change from baseline)
Height 0.009 Low
Schedule 0.017 2 weekly
Sex 0.023 Female
IgE 0.032 High
Number of severe exacerbations
Height o0.001 Low
Weight 0.002 Low
Age 0.006 High
Sex 0.027 Female
Visits to doctor in last year 0.045 Low
Morning PEF 0.051 Low
Qualifying FEV1 reversibility 0.098 Low
Incidence of any severe exacerbations
Height 0.014 Low
ICS 0.017 Low
Weight 0.036 Low
Sex 0.057 Female
Prior intubation 0.058 Yes
Mould allergy 0.069 Yes
Morning PEF 0.070 Low
Missed work/school days 0.076 High
Quality of life (X 0.5 point improvement in AQLQ score)
GINA clinical features o0.001 Low
IgE 0.031 High
Per cent predicted FEV1 0.038 High
Rescue medication use 0.040 Low
Daytime symptom score 0.047 Low
Schedule 0.053 2 weekly
Morning PEF 0.060 High
Total symptom score 0.060 Low
Sex 0.078 Male
Height 0.082 High
Physician’s overall assessment (complete control or marked improvement)
IgE 0.026 High
ICS use 0.037 Low
Per cent predicted FEV1 0.042 High
Missed work/school days 0.049 High
Lung function (X 200mL improvement in FEV1)
Days since previous exacerbation 0.024 Low
Number of exacerbations in previous year 0.052 High
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Table 3 Efficacy outcomes in subgroups of patients divided in quartiles according to baseline IgE in the pooled population.
Outcome measure Baseline IgE subgroup
0–75 IU/mL 76–147 IU/mL 148–273 IU/mL X274 IU/mL
Omal. Control Omal. Control Omal. Control Omal. Control
(n ¼ 602) (n ¼ 453) (n ¼ 659) (n ¼ 421) (n ¼ 634) (n ¼ 444) (n ¼ 616) (n ¼ 465)
Annualized asthma exacerbation rate 1.28 1.48 0.85 1.47 0.80 1.47 0.76 1.43
D D–13.8% D–41.9% D–45.4% D–46.5%
P-value 0.227 o 0.001 o 0.001 o 0.001
Annualized severe exacerbation rate 0.09 0.22 0.07 0.11 0.07 0.20 0.05 0.17
D D–59.7% D–38.0% D–66.4% D–68.8%
P-value o 0.05 0.218 o 0.001 o 0.001
Annualized total emergency visit rate 0.44 0.64 0.32 0.60 0.35 0.89 0.33 0.55
D D–31.0% D–46.3% D–60.9% D–40.8%
P-value 0.141 o 0.05 o 0.01 o 0.05
FEV1 net benefit
y, % 4.1 –0.5 11.7 3.4 7.9 0.5 22.3 2.9
P-value 0.289 0.057 0.099 o 0.001
AQLQ improvement X 0.5 points, % 58.7 54.2 67.5 54.0 68.7 50.0 68.9 52.5
P-value 0.298 o 0.001 o 0.001 o 0.001
Physician’s overall assessmentz, % 49.3 40.2 59.3 42.9 66.6 36.1 67.1 36.2
P-value o 0.05 o 0.001 o 0.001 o 0.001
D denotes the reduction in rate for omalizumab vs. placebo.
yPatients with improvement in FEV1X200mL minus those with worsening X200mL, statistical testing was performed using
proportions of patients with an improvement, a worsening, or no meaningful change.
zComplete control or marked improvement, P-value for the overall distribution of physician’s overall assessment. Not all endpoints
were assessed in each study.
Table 4 Annualized clinically significant exacerbation rates by various responder definitions (INNOVATE).
Response measure Clinically significant exacerbations
% Responders Responder Non-responder
n Rate (SD) n Rate (SD)
Physician’s overall assessment (complete control or marked improvement) 61 118 0.6 (1.31) 77 2.6 (6.39)
AQLQX0.5 improvement 61 124 0.8 (1.45) 80 1.7 (2.90)
FEV1X200mL improvement 44 90 1.2 (2.39) 116 1.1 (2.00)
Daytime symptom score X1.0 reduction 21 36 0.3 (0.83) 140 1.7 (4.96)
Nocturnal symptom score X1.0 reduction 18 32 0.4 (0.87) 146 1.6 (4.87)
Night awakenings reduced X1/week and by 50% 32 57 0.8 (2.13) 121 1.7 (5.18)
Imputed exacerbations resulted in some patients with high exacerbation rates not being included in all analysis populations.
Therefore, to enable meaningful direct comparisons, all exacerbation rates presented are without imputation. Clinically significant
exacerbations were defined as a worsening of asthma requiring treatment with systemic corticosteroids.
J. Bousquet et al.1488agreement between investigator and patient assessments in
INNOVATE and 82.6% agreement in the pooled analysis.Supportive criteria for physician’s overall assessment
response
No single response measure (out of more than 50 tested) or
combination of measures had a meaningful level of bothsensitivity and specificity for detecting physician’s overall
assessment responders (data not shown).
Comparison of exacerbation rates in responders (physi-
cian’s overall assessment) and a patient population with
total baseline IgEX76 IU/mL.
The reduction in asthma exacerbation rates vs. placebo
were greater in responders (according to physician’s
overall assessment) than in the overall omalizumab-treated
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Table 5 Frequency of patients within one responder category who also meet the criteria of other responder criteria
(INNOVATE).
Responder
definition
Physician’s overall
assessment
(complete
control/marked
improvement), %
AQLQX0.5
improvement, %
FEV1X200mL
improvement,
%
Nocturnal
symptomsX1.0
reduction, %
Daytime
symptomsX1.0
reduction, %
Night awakenings
reducedX1/week
andX50%, %
Physician’s overall
assessment
(complete control
or marked
improvement)
– 79.6 71.0 82.1 83.3 73.1
AQLQX0.5
improvement
77.2 – 68.1 92.9 86.7 76.9
FEV1X200mL
improvement
48.5 48.0 – 57.1 53.3 48.1
Nocturnal
symptomsX1.0
reduction
22.8 26.5 23.2 – 73.3 50.0
Daytime
symptomsX1.0
reduction
24.8 26.5 23.2 78.6 – 50.0
Night awakenings
reducedX1/week
andX50%
37.6 40.8 36.2 92.9 86.7 –
Highlighted values indicate470% overlap between responder criteria; data should be read as, for example, physicians overall
assessment was able to classify as responders 82.1% of patients identified by nocturnal symptoms, whereas nocturnal symptoms could
only identify 22.8% of physician’s overall assessment responders.
Predicting response to omalizumab in asthma 1489population and were observed irrespective of baseline IgE
(Figs. 1a and 1b).Discussion
Predicting response to omalizumab in patients with inade-
quately controlled severe persistent allergic asthma is of
great clinical relevance. Our results show that it is difficult
to predict which patients will gain most benefit from
treatment with omalizumab based on pre-treatment base-
line characteristics. On the other hand, patients who
respond to omalizumab can be identified by physician’s
overall assessment of treatment. This simple measurement
can be used to determine whether treatment should
continue beyond an initial 16-week trial of omalizumab
therapy.
In the INNOVATE study, baseline total IgE was the only
consistent predictor of response to emerge from the
univariate and multivariate analyses. However, this finding
was only partially supported in the detailed evaluation of
the relationship between efficacy and baseline total IgE in a
large pooled population. Exacerbation rates in the control
group were similar across all IgE levels, which shows a
medical need irrespective of baseline IgE and highlights a
poor correlation between total IgE and disease severity. The
omalizumab dosing table ensures that patients are broughtdown to similar on-treatment free IgE levels. Although lower
IgE was predictive of smaller treatment benefits in
univariate/multivariate analyses of INNOVATE data, pooled
analysis of baseline total IgE levels across clinically
important response measures did not consistently support
this. It is notable that the effect of treatment was not
linearly related to baseline total IgE, suggesting the
usefulness of a dosing table based upon body weight and
IgE. Further study is needed to investigate the potential
predictive value of other biomarkers including baseline
levels of specific IgE.
The physician’s overall assessment was found to be the
most meaningful measure of response to omalizumab
therapy, with around 61% of the overall omalizumab-treated
population identified as responders. Importantly, the physi-
cian’s overall assessment was able to identify patients who
experienced markedly lower exacerbation rates, which is a
key treatment goal in this severe population. Single
measures of response, with the exception of FEV1, also
discriminated exacerbation response. However, these mea-
sures only identified up to approximately 50% of the true
responder population. It should be noted, however, that the
AQLQ (another broad measure) also identified a high
proportion of responders and discriminated clinically sig-
nificant exacerbation response, but was not discriminative
for severe exacerbation response. The Asthma Control
Questionnaire21 may have been useful, but was not used in
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Table 6 Annualized exacerbation rates, unscheduled healthcare utilization and other asthma control measures by
physician’s overall assessment responders and non-responders to omalizumab (INNOVATE).
Responder Non-responder
Clinically significant exacerbations
Rate, mean (SD) 0.6 (1.31) 2.6 (6.39)
Severe exacerbations
Rate, mean (SD) 0.2 (0.6) 1.4 (6.1)
Hospitalizationsy
Patients hospitalized in treatment phase, % 2.5 9.1
Rate, mean (SD) 0.03 (0.22) 0.10 (0.35)
Emergency room visitsy
Rate, mean (SD) 0.02 (0.17) 0.17 (0.80)
Unscheduled physician visitsy
Rate, mean (SD) 0.11 (0.44) 0.49 (1.31)
Any unscheduled healthcare utilization
Rate, mean (SD) 0.20 (0.61) 1.50 (6.14)
Asthma symptom score, mean (SD) –1.24 (1.82) –0.47 (1.72)
Night awakenings due to asthma per week, mean (SD) –1.23 (2.22) –0.28 (2.74)
Daily rescue medication use (puffs), mean (SD) –2.32 (3.93) –0.17 (3.79)
FEV1 (mL), mean (SD)
 252 (521) 87 (445)
AQLQ improvementX0.5-point, % of patients 78.8 34.7
yRates in the previous year were similar for responders and non-responders.
Values are changes from baseline.
J. Bousquet et al.1490the studies as these were often planned before it was
available. However, the questionnaire is being used in
ongoing studies. Responders according to the physician’s
overall assessment also experienced marked improvements
in overall asthma control and lower rates of unscheduled
medical interventions. Responders had 40–70% fewer clini-
cally significant and severe exacerbations, respectively, and
almost three times the improvement in FEV1 compared with
non-responders. Furthermore, physician’s overall assess-
ment was shown to be sensitive to patients’ perceptions of
improved quality of life, as indicated by the correlation with
AQLQ score.
In our analysis of supportive objective measures for
identifying the physician’s overall assessment responders
(diagnostic utility analysis), no single or combined measures
of response (including symptoms and lung function) were
able to provide an acceptable level of both sensitivity and
specificity in detecting physician’s overall assessment
responders. Large improvements in daytime or night-time
symptoms or quality of life would strongly support con-
tinuation of therapy; however, patients who do not meet
these criteria should not be discontinued from omalizumab
therapy on this basis alone as there is a very significant
proportion of patients who experience significant benefit
from omalizumab without achieving these arbitrary thresh-
olds using single aspect clinical criteria. This provides
further evidence to support the recent shift towards broad,
composite measures of asthma control within treatment
guidelines.Patients who responded to omalizumab according to the
physician’s overall assessment had greater reductions in
clinically significant and severe exacerbation rates than
patients with baseline total IgEX76 IU/mL. Moreover,
excluding patients with IgEo76 IU/mL did not further
improve discrimination of exacerbation outcomes in respon-
ders. These data provide further evidence of the limitations
of selecting a subpopulation of patients based on total
baseline IgE within the range specified for omalizumab
therapy (30–700 IU/mL).
It is important to recognize that not all patients respond
to omalizumab treatment and that stopping therapy in non-
responders will minimize unwarranted drug exposure and
healthcare expenditure. Physicians prescribing omalizumab
need to undertake an evaluation of response to therapy
after an appropriate period of treatment. Based on both the
cellular mechanism of action and clinical study data
assessment of omalizumab at 16 weeks allows patients to
achieve maximum benefit,11 and would also comply with
current guideline recommendations for regular clinical
review every 1–6 months in patients with persistent
asthma17 as well as with the labelling for omalizumab in
the European Union.
In conclusion, these data show that it is difficult to reliably
predict which patients will derive the greatest benefit from
omalizumab therapy based on pre-treatment baseline char-
acteristics. In addition, it appears that physician’s overall
assessment after 16 weeks of omalizumab therapy is the most
meaningful measure of treatment response.
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Figure 1 Relative rates of (a) clinically meaningful exacerba-
tions and (b) severe exacerbations in patients with baseline
IgEX76 IU/mL, physician’s overall assessment responders,
patients with both of these criteria and the overall omalizu-
mab-treated population (INNOVATE study). Data is shown as rate
ratios (omalizumab:placebo) calculated using the Poisson
regression model.
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